Collaborations & Alliances

CellSight, Boehringer form Alliance for Anti-tumor T-Cell Activation Technology

The new technology could help to accelerate the development of critical immuno-oncological therapies

CellSight Technologies, a US-based PET (Positron Imaging Tomography) imaging company, is collaborating with Boehringer Ingelheim to evaluate CellSight’s PET imaging tracer, VisAcT. The goal of the alliance is future use of VisAcT in the development and monitoring of immune-oncological therapies.   A clinical trial to evaluate immunological response to PD-1 checkpoint inhibition in squamous cell carcinoma of the head and neck is currently ongoing.  The focus of the trial is to deter...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters